Schizophrenia

If you are suffering from schizophrenia, you may benefit from participating in one of our clinical trials, which offer you treatment with novel substances that have not yet reached market approval and can therefore not be prescribed otherwise.

Regarding schizophrenia, we are currently performing the following clinical trials:

SNR04

An adaptive, phase IIB/III, multi-center, prospective, randomized, double-blind, placebo-controlled study of the safety and efficacy of NaBen® (sodium benzoate), a D-amino acid oxidase inhibitor, as an add-on treatment for schizophrenia in adults.

You might consider study participation if the following inclusion criteria apply:

  • You have been diagnosed with schizophrenia.
  • You are between 18 and 45 years of age.
  • You have been on stable antipsychotic medication for a minimum of 8 weeks (or longer in case of treatment with a long-acting injectable).
  • You have never received clozapine treatment.
  • A caregiver is available and willing to accompany you to the study visits or is available for telephone queries.
  • You are not taking any recreational drugs (exceptions: nicotine, caffeine).

Duration of Study: up to 68 weeks

We will gladly discuss further in- and exclusion criteria as well as study procedures during a personal meeting.

SNR05

An adaptive phase II/III, double-blind, randomized, placebo controlle, two-part, dose-finding, multi-center study of the safety and efficacy of NaBen® (sodium benzoate), a D-amino acid oxicdase inhibitor, as an add-on therapy with clozapine, for residual symptoms of refractory schizophrenia in adults.

You might consider study participation if the following inclusion criteria apply:

  • You have been diagnosed with treatment-resistant schizophrenia and have been suffering from treatment-refractory symptoms for a minimum of 3 months.
  • You are between 18 and 55 years of age.
  • At study entry, you have been treated with clozapine for at least 6 months at a stable dose for at least 3 months.
  • A caregiver is available and willing to accompany you to the study visits or is available for telephone queries.
  • You are not taking any recreational drugs (exceptions: nicotine, caffeine).

Duration of Study: 12 weeks

We will gladly discuss further in- and exclusion criteria as well as study procedures during a personal meeting.

For further information, please contact our site staff:

Dinah Schramm, telephone number: 06131-17-6101,
 dinah.schramm@unimedizin-mainz.de

and/or

Ricarda Endler, telephone number: 06131-17-6102,
 ricarda.endler@unimedizin-mainz.de

or

or get in touch with us via our general e-mail address:
 SPE@unimedizin-mainz.de

University Medical Center Mainz
Study Center for Clinical Trials in Mental Disorders
Untere Zahlbacher Str. 8
55131 Mainz
Germany